Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$12.07 - $18.46 $5.01 Million - $7.66 Million
-415,174 Reduced 77.65%
119,526 $1.76 Million
Q3 2023

Nov 14, 2023

BUY
$18.08 - $23.45 $6.32 Million - $8.2 Million
349,700 Added 189.03%
534,700 $9.79 Million
Q1 2023

May 15, 2023

BUY
$27.71 - $40.93 $1.25 Million - $1.84 Million
45,000 Added 32.14%
185,000 $5.43 Million
Q4 2022

Feb 14, 2023

BUY
$29.75 - $39.26 $3.12 Million - $4.12 Million
105,000 Added 300.0%
140,000 $5.17 Million
Q3 2022

Nov 14, 2022

BUY
$17.15 - $30.92 $600,250 - $1.08 Million
35,000 New
35,000 $985,000

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.